Metagenomic next-generation sequencing (mNGS) offers a powerful, unbiased solution for detecting bacterial pathogens in clinical samples, especially when traditional culture methods are slow or inconclusive. Unlike targeted molecular techniques, mNGS sequences all bacterial DNA within a sample, enabling broad-range detection without prior assumptions about the pathogen, or requirement of sequence-specific primers for target-specific or broad range PCR amplification. This approach allows for rapid identification of both common and rare bacteria directly from clinical specimens, providing species-level resolution critical for guiding targeted antimicrobial treatment.

mNGS is particularly valuable in diagnosing infections in sterile body sites or invasive diseases where pathogens are difficult to culture. It is also effective in cases where empirical treatment may be ineffective, enabling timely and accurate identification that significantly improves patient outcomes.